Look at the stock price pal...It is a disgrace that this company is still under HUGIN hands....A disgrace.....Good Luck to you.... I am mostly long but I own lots puts too now....And of when it goes to 50's will selll bunch of puts ////
Goldman has a $54 target and missed the run from 51 to 68. They had a sell on BIIB at 54 and it ran to 120. Tehy told clients to load DNDN agressively mid-40s right before it fell to 7.
And BY THE WAY - while incompetent and always wrong Sapna S has a neutral on CELG, their asset management decision has been buying CELG shares hand over fist the pastr quarter and are long into ASH. You should understand how this works.
CELG down with mkt down 100 today but will rebound.
Yes - the top five oral presentations this yr will be very positive for the first time in 5 yrs.
There is for the first time no Velcade trial data that can hurt us if you dive into the presentations...
They will shake the tree over and over with weak European news etc - but CELG is holding up quite well.
First webcast of ASH analyst meeting ever is indeed a tell
Biotech - ASH preview = we will be attending the American Society of Hematology conference from December 10-13, where Celgene and Incyte will present updated Phase III data from trials of Revlimid and Jakafi, respectively. We believe expectations heading into the conference for Celgene are low, potentially allowing CELG shares to buck the trend and do well exiting the conference. We expect the focus for Celgene to be on subgroup analysis of the MM-015 trial, specifically ages 65-75, where a statistically significant improvement in progression free survival (PFS) could confirm “trends” toward an overall survival (OS) benefit, despite a crossover trial design. In addition, we expect Phase II data for pomalidomide in refractory multiple myeloma to support an accelerated filing in 1Q12. For Incyte, investor focus remains on Jakafi’s launch. We expect physicians to confirm a desire to use Jakafi, but 1Q12 sales will likely be impacted by the Medicare donut hole.
This yrs ash will be the best in 6 yrs - its looking like the top 6 presentations will all be positive.
Late vol on down days - millions on the uptick and the INCREASE in put open interest means the big boys knocked it down to sell puts to open to the scared uninformed guys like ortigia who assumes every ash is the same even though we have 200+ different presentations than last yr including 10 that completely take last yrs SPM issue that hit CELG off the table.
Look at the chart - perfect for a huge run coming. Ortigia is blinded by emotion - look at the chart, the abstracts and the facts. We also have Jackie F this yr ready
yeah, I looked at the daily chart too and after it dropped to 60.90, they ran it up to even and bought more to close green. this wants to go higher. how much and how fast is the question.